One-Shot HIV Vaccine Shows Promise in Primate Study

For the first time ever, researchers have created an HIV vaccine that produces virus-fighting antibodies after a single shot.

Scientists at The Wistar Institute in Philadelphia tested their experimental vaccine in nonhuman primates and saw results within three weeks. That's revolutionary in a field where typical vaccine protocols require seven to ten injections before showing any protection at all.

Dr. Amelia Escolano and her team did something nobody else dared to try. They removed a sugar molecule that everyone believed was essential for an HIV vaccine to work.

The gamble paid off. Their engineered protein, called WIN332, triggered a new type of antibody that doesn't need that sugar to fight HIV.

After just one injection, the primates showed low but detectable protection against the virus. A second booster shot increased that protection significantly.

"If this approach proves successful, we could potentially achieve desired immunity with just three injections," said Dr. Ignacio Relano-Rodriguez, the study's first author. "This would make vaccination protocols shorter and more affordable."

The discovery goes beyond just fewer shots. The research revealed a completely new class of HIV-fighting antibodies that scientists didn't know existed.

These "Type II" antibodies work differently from the previously known Type I antibodies. That discovery expands the toolkit researchers have for developing vaccines that protect against the many different HIV strains circulating worldwide.

The Ripple Effect

Shorter vaccination schedules mean more than convenience. They mean greater access in regions where healthcare infrastructure makes multiple visits challenging.

Fewer required doses also means lower costs. That matters enormously for global health efforts fighting a virus that still infects 1.3 million people each year.

Major global health organizations have already taken notice. They're now working with the Wistar team to move WIN332 toward human clinical trials.

Meanwhile, the researchers continue testing and designing follow-up vaccines that could work in a shortened series. Each step brings the medical community closer to a goal that once seemed impossible.

The findings appeared in Nature Immunology this February, marking a turning point in the decades-long effort to develop an effective HIV vaccine.